Analysis of Human Dopamine D3 Receptor Quaternary Structure*

Background: The dopamine D3 receptor can form dimers/oligomers, but the molecular basis for this is poorly defined. Results: Molecular modeling, mutagenesis, and analysis of inactive state receptor crystal structures allowed assessment of models of receptor organization. Conclusion: The dopamine D3 receptor can assume different dimeric and a rhombic tetrameric arrangements. Significance: These findings provide understanding of the molecular basis of D3 receptor quaternary structure. The dopamine D3 receptor is a class A, rhodopsin-like G protein-coupled receptor that can form dimers and/or higher order oligomers. However, the molecular basis for production of these complexes is not well defined. Using combinations of molecular modeling, site-directed mutagenesis, and homogenous time-resolved FRET, the interfaces that allow dopamine D3 receptor monomers to interact were defined and used to describe likely quaternary arrangements of the receptor. These were then compared with published crystal structures of dimeric β1-adrenoreceptor, μ-opioid, and CXCR4 receptors. The data indicate important contributions of residues from within each of transmembrane domains I, II, IV, V, VI, and VII as well as the intracellular helix VIII in the formation of D3-D3 receptor interfaces within homo-oligomers and are consistent with the D3 receptor adopting a β1-adrenoreceptor-like quaternary arrangement. Specifically, results suggest that D3 protomers can interact with each other via at least two distinct interfaces: the first one comprising residues from transmembrane domains I and II along with those from helix VIII and a second one involving transmembrane domains IV and V. Moreover, rather than existing only as distinct dimeric species, the results are consistent with the D3 receptor also assuming a quaternary structure in which two transmembrane domain I-II-helix VIII dimers interact to form a ”rhombic” tetramer via an interface involving residues from transmembrane domains VI and VII. In addition, the results also provide insights into the potential contribution of molecules of cholesterol to the overall organization and potential stability of the D3 receptor and possibly other GPCR quaternary structures.

[1]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[2]  B. Foll,et al.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction , 2015, European Neuropsychopharmacology.

[3]  G. Milligan,et al.  The Molecular Basis of Oligomeric Organization of the Human M3 Muscarinic Acetylcholine Receptor , 2015, Molecular Pharmacology.

[4]  G. Milligan,et al.  Regulation of Oligomeric Organization of the Serotonin 5-Hydroxytryptamine 2C (5-HT2C) Receptor Observed by Spatial Intensity Distribution Analysis , 2015, The Journal of Biological Chemistry.

[5]  B. O'dowd,et al.  A peptide targeting an interaction interface disrupts the dopamine D1‐D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. W. Wells,et al.  Coupling of G Proteins to Reconstituted Monomers and Tetramers of the M2 Muscarinic Receptor* , 2014, The Journal of Biological Chemistry.

[7]  R. Stevens,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[8]  Martin J. Lohse,et al.  G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives , 2014, Pharmacological Reviews.

[9]  A. Kusumi,et al.  Single-molecule imaging revealed dynamic GPCR dimerization. , 2014, Current opinion in cell biology.

[10]  Steven M. Moss,et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug , 2014, Nature.

[11]  G. Milligan.  The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization , 2013, Molecular Pharmacology.

[12]  V. Raicu,et al.  The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. , 2013, The Biochemical journal.

[13]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[14]  Jianyun Huang,et al.  Crystal Structure of Oligomeric β1-Adrenergic G Protein- Coupled Receptors in Ligand-Free Basal State , 2013, Nature Structural &Molecular Biology.

[15]  M. Niv,et al.  Computational and Experimental Analysis of the Transmembrane Domain 4/5 Dimerization Interface of the Serotonin 5-HT1A Receptor , 2012, Molecular Pharmacology.

[16]  H. Attrill,et al.  The role of cholesterol on the activity and stability of neurotensin receptor 1. , 2012, Biochimica et biophysica acta.

[17]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[18]  Gianluigi Caltabiano,et al.  Impact of Helix Irregularities on Sequence Alignment and Homology Modeling of G Protein‐Coupled Receptors , 2012, Chembiochem : a European journal of chemical biology.

[19]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[20]  R. Stevens,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[21]  Leigh A. Stoddart,et al.  Functional Homomers and Heteromers of Dopamine D2L and D3 Receptors Co-exist at the Cell Surface , 2012, The Journal of Biological Chemistry.

[22]  G. Milligan,et al.  Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A* , 2011, The Journal of Biological Chemistry.

[23]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[24]  H. Hamm,et al.  Interaction of a G protein with an activated receptor opens the interdomain interface in the alpha subunit , 2011, Proceedings of the National Academy of Sciences.

[25]  Catherine L. Worth,et al.  GPCR-SSFE: A comprehensive database of G-protein-coupled receptor template predictions and homology models , 2011, BMC Bioinformatics.

[26]  B. O'dowd,et al.  Dopamine Receptor Homooligomers and Heterooligomers in Schizophrenia , 2011, CNS neuroscience & therapeutics.

[27]  Davide Provasi,et al.  Making Structural Sense of Dimerization Interfaces of Delta Opioid Receptor Homodimers , 2011, Biochemistry.

[28]  K. Fuxe,et al.  Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. , 2010, Biochemical and biophysical research communications.

[29]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[30]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[31]  P. Seeman,et al.  Cocaine self‐administration markedly increases dopamine D2 receptor negative cooperativity for dopamine binding: A receptor dimer‐based analysis , 2010, Synapse.

[32]  Jinbin Xu,et al.  [3H]4‐(dimethylamino)‐N‐(4‐(4‐(2‐methoxyphenyl)piperazin‐1‐yl) butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate‐putamen , 2010, Synapse.

[33]  M. Lohse.  Dimerization in GPCR mobility and signaling. , 2010, Current opinion in pharmacology.

[34]  M. Millan,et al.  Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. , 2010, Current opinion in pharmacology.

[35]  R. Abagyan,et al.  Secretin Occupies a Single Protomer of the Homodimeric Secretin Receptor Complex , 2010, The Journal of Biological Chemistry.

[36]  Gregory I. Mashanov,et al.  Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules , 2010, Proceedings of the National Academy of Sciences.

[37]  L. Pardo,et al.  Ligand-regulated oligomerization of β2-adrenoceptors in a model lipid bilayer , 2009, The EMBO journal.

[38]  Graeme Milligan,et al.  G protein‐coupled receptor hetero‐dimerization: contribution to pharmacology and function , 2009, British journal of pharmacology.

[39]  Marta Filizola,et al.  Dopamine D2 receptors form higher order oligomers at physiological expression levels , 2008, The EMBO journal.

[40]  N. Tinel,et al.  Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.

[41]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[42]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[43]  E. Kandel,et al.  Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning , 2006, Neuron.

[44]  Marta Filizola,et al.  Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[46]  Graeme Milligan,et al.  G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology , 2004, Molecular Pharmacology.

[47]  S. Tsai,et al.  Dopamine receptor hetero-oligomerization in the pathogenesis of schizophrenia: qualitative as opposed to quantitative notions of dopaminergic receptors , 2003, Schizophrenia Research.

[48]  Lei Shi,et al.  The Fourth Transmembrane Segment Forms the Interface of the Dopamine D2 Receptor Homodimer* , 2003, The Journal of Biological Chemistry.

[49]  M. Millan,et al.  Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[50]  J. W. Wells,et al.  Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. , 2002, Biochemistry.

[51]  J. Joyce,et al.  D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period , 2001, Synapse.

[52]  S. Sprang,et al.  Crystal structure of the adenylyl cyclase activator Gsalpha. , 1997, Science.

[53]  J. Morrison,et al.  Expression of Dopamine D3 Receptor Dimers and Tetramers in Brain and in Transfected Cells* , 1997, The Journal of Biological Chemistry.

[54]  R. Stevens,et al.  Structure of the human k-opioid receptor in complex with JDTic , 2012 .

[55]  D. Sibley.  Handbook of contemporary neuropharmacology , 2007 .

[56]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .